Literature DB >> 28411188

Raf Kinase Inhibitor Protein Preferentially Promotes TLR3-Triggered Signaling and Inflammation.

Rongrong Lai1, Meidi Gu1, Wei Jiang2, Wenlong Lin1, Penglei Xu1, Zhiyong Liu1, He Huang3, Huazhang An4, Xiaojian Wang5.   

Abstract

Raf kinase inhibitor protein (RKIP) protects against host immunological responses in nematodes and Drosophila Whether RKIP functions in innate immune responses in mammals remains unknown. In this article, we report that RKIP preferentially regulates the TLR3-mediated immune response in macrophages. RKIP deficiency or silencing significantly decreases polyinosinic:polycytidylic acid [Poly(I:C)]-induced IFN-β, IL-6, and TNF-α production without affecting the counterpart induced by LPS or CpG. Compared with their wild-type counterparts, RKIP-deficient mice produce less IFN-β, IL-6, and TNF-α in serum and display decreased lethality upon peritoneal Poly(I:C) plus d-galactosamine injection. Mechanistically, RKIP interacts with TBK1 and promotes the Poly(I:C)-induced TANK-binding kinase 1/IRF3 activation. Simultaneously, RKIP enhances the Poly(I:C)-induced interaction between TGF-β-activated kinase 1 and MAPK kinase 3 (MKK3), thus promoting MKK3/6 and p38 activation. We further demonstrated that Poly(I:C) treatment, but not LPS treatment, induces RKIP phosphorylation at S109. This action is required for RKIP to promote TANK-binding kinase 1 activation, as well as the interaction between TGF-β-activated kinase 1 and MKK3, which lead to activation of the downstream IRF3 and p38, respectively. Therefore, RKIP acts as a positive-feedback regulator of the TLR3-induced inflammatory response and may be a potential therapeutic target for inflammatory disease.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28411188     DOI: 10.4049/jimmunol.1601672

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Raf kinase inhibitor protein negatively regulates FcεRI-mediated mast cell activation and allergic response.

Authors:  Wenlong Lin; Fasheng Su; Rahul Gautam; Ning Wang; Yuanyuan Zhang; Xiaojian Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-03       Impact factor: 11.205

2.  The inhibitor effect of RKIP on inflammasome activation and inflammasome-dependent diseases.

Authors:  Qiang Qin; Huan Liu; Jia'nan Shou; Yu Jiang; Hong Yu; Xiaojian Wang
Journal:  Cell Mol Immunol       Date:  2020-09-08       Impact factor: 11.530

Review 3.  RKIP as an Inflammatory and Immune System Modulator: Implications in Cancer.

Authors:  Maria Gabriela-Freitas; Joana Pinheiro; Ana Raquel-Cunha; Diana Cardoso-Carneiro; Olga Martinho
Journal:  Biomolecules       Date:  2019-11-22

4.  A Functional Network Model of the Metastasis Suppressor PEBP1/RKIP and Its Regulators in Breast Cancer Cells.

Authors:  Mahmoud Ahmed; Trang Huyen Lai; Wanil Kim; Deok Ryong Kim
Journal:  Cancers (Basel)       Date:  2021-12-03       Impact factor: 6.639

5.  A Negative Regulatory Role for RKIP in Breast Cancer Immune Response.

Authors:  Vu N Bach; Jane Ding; Miranda Yeung; Taylor Conrad; Hussain N Odeh; Paige Cubberly; Christopher Figy; Han-Fei Ding; Robert Trumbly; Kam C Yeung
Journal:  Cancers (Basel)       Date:  2022-07-24       Impact factor: 6.575

6.  Botanically-Derived Δ9-Tetrahydrocannabinol and Cannabidiol, and Their 1:1 Combination, Modulate Toll-like Receptor 3 and 4 Signalling in Immune Cells from People with Multiple Sclerosis.

Authors:  John-Mark Fitzpatrick; Becky Hackett; Lisa Costelloe; William Hind; Eric J Downer
Journal:  Molecules       Date:  2022-03-08       Impact factor: 4.411

7.  Elevated microRNA-129-5p level ameliorates neuroinflammation and blood-spinal cord barrier damage after ischemia-reperfusion by inhibiting HMGB1 and the TLR3-cytokine pathway.

Authors:  Xiao-Qian Li; Feng-Shou Chen; Wen-Fei Tan; Bo Fang; Zai-Li Zhang; Hong Ma
Journal:  J Neuroinflammation       Date:  2017-10-23       Impact factor: 8.322

Review 8.  Insights of RKIP-Derived Suppression of Prostate Cancer.

Authors:  Ying Dong; Xiaozeng Lin; Anil Kapoor; Yan Gu; Hui Xu; Pierre Major; Damu Tang
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.